Impact of chronic obstructive pulmonary disease on respiratory status and quality of life in newly diagnosed patients with lung cancer

Respirology

Volumn 12, Issue 2, 2007, Pages 240-247

  Mohan, Anant ^a   Mohan, Charu ^a   Pathak, Ashutosh K ^a   Pandey, Ravinder M ^a   Guleria, Randeep ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

COPD; Karnofsky Performance status; Lung cancer; Quality of life

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DYSPNEA; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY FUNCTION; SPIROMETRY; THORAX PAIN; VISUAL ANALOG SCALE;

CROSS-SECTIONAL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SPIROMETRY; VITAL CAPACITY;

EID: 33846906187     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.01038.x     Document Type: Article

References (36)

1. Parkin DM, Pisani P, Ferlay J. Estimation of the worldwide incidence of 18 major cancers in 1985. Int. J. Cancer 1993; 54: 594-606.
2. Thatcher N, Spiro S. New Perspective in Lung Cancer. BMJ, London, 1994.
3. Aisner J, Belani CP. Lung cancer: recent changes and expectations of improvements. Semin. Oncol. 1993; 20: 383-9.
4. Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Impact of dyspnea, pain, and fatigue on daily activities in ambulatory patients with advanced lung cancer. J. Pain Symptom Manage. 2002; 23: 417-23.
5. Ruffin RE, Wilson DH, Chittleborough CR, Southscott AM, Smith B, et al. Multiple respiratory symptoms predict quality of life in chronic lung disease: a population based study of Australian adults. Qual. Life Res. 2000; 9: 1031-9.
6. Mahler DA, Faryniarz K, Tomlinson D, Colice GL, Robins AG, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 102: 395-401.
7. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 2000; 117: 1627-32.
8. Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006; 129: 1305-12.
9. Lopez-Encuentra A, Astudillo J, Cerezal J, Gonzalez-Aragoneses F, Novoa N, et al. Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur. J. Cardiothorac. Surg. 2005; 27: 8-13.
10. Sekine Y, Behnia M, Fujisawa T. Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC. Lung Cancer 2002; 37: 95-101.
11. Larsen KR, Svendsen UG, Milman N, Brenoe J, Peersen BN. Cardiopulmonary function at rest and during exercise after resection for bronchial carcinoma. Ann. Thorac. Surg. 1997; 64: 960-4.
12. Bolliger CT, Jordan P, Soler M, Stulz P, Tamm M, et al. Pulmonary function and exercise capacity after lung resection. Eur. Respir. J. 1996; 9: 415-21.
13. Pelkonen M, Notkola IL, Tukiainen H, Tervahauta M, Tuomilehto J, et al. Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries Study. Thorax 2001; 56: 703-7.
14. Gritz ER. Smoking and smoking cessation in cancer patients. Br. J. Addic. 1991; 86: 549-54.
15. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex associated differences in presentation and survival in patients with lung cancer. J. Clin. Oncol. 1990; 8: 1402-7.
16. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-17.
17. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed.) Evaluation of Chemotherapeutic Agents. (Symposium, Microbiology Section, New York Academy of Medicine.) Columbia University Press, New York, 1949; 191-205.
18. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 80-6.
19. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am. J. Respir. Crit. Care Med. 1998; 158: 1384-7.
20. Mador MJ, Kufel TJ. Reproducibility of VAS measurements of dyspnea in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1992; 146: 82-7.
21. American Thoracic Society. Standardization of spirometry, 1994 update. Am. J. Respir. Crit. Care Med. 1995; 152: 1107-36.
22. American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am. Rev. Respir. Dis. 1991; 144: 1202-18.
23. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am. Rev. Respir. Dis. 1981; 123: 659-64.
24. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-76.
25. Saxena S, Chandiramani K, Bhargava R. WHOQOL-Hindi: a questionnaire for assessing quality of life in health care settings in India. World Health Organization Quality of Life. Natl Med. J. India 1998; 11: 160-5.
26. Groen HJM, Van Der mark TW, Van Der Leest AHD, De Vries EGE, Mulder NH. Pulmonary function changes in lung cancer patients treated with radiation with or without carboplatin. Am. J. Respir. Crit. Care Med. 1995; 152: 2044-8.
27. Svobodnik A, Yang P, Novotny PJ, Bass E, Garces YI, et al. Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis. Mayo Clin. Proc. 2004; 79: 1024-30.
28. Prasad R, James P, Kesarwani V, Gupta R, Pant MC, et al. Clinicopathological study of bronchogenic carcinoma. Respirology 2004; 9: 557-60.
29. Kurushima K, Satoh H, Ishikawa H, Yamashita YT, Homma T, et al. Lung cancer patients with chronic obstructive pulmonary disease. Oncol. Rep. 2001; 8: 63-5.
30. Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, et al. Impact of respiratory symptoms and pulmonary functions on quality of life of long-term survivors of non-small cell lung cancer. Chest 2004; 125: 439-45.
31. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur. Respir. J. 1994; 7: 1350-64.
32. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 1993; 85: 365-76.
33. Buccheri GF, Ferrigno D, Tamburini M, Brunelli C. The patient's perception of his own quality might have an adjunctive prognostic significance in lung cancer. Lung Cancer 1995; 12: 45-58.
34. Hopwood PH, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br. J. Cancer 1995; 71: 633-6.
35. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur. J. Cancer 1996; 32A: 1135-41.
36. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K. Six-minute walking and pulmonary function test outcomes during the early period after lung cancer surgery with special reference to patients with chronic obstructive pulmonary disease. Jpn J. Thorac. Cardiovasc. Surg. 2004; 52: 113-19.